ArticleBMC gastroenterology2026
Efficacy and safety of dual biologics or combination therapy with JAK inhibitors in refractory inflammatory bowel disease: a retrospective single-center real-world study from China.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThere is limited data on the efficacy and safety of combination therapy of dual biologics or small molecules combined with biologics in inflammatory bowel disease (IBD) patients in China. The present retrospective study determined the efficacy and safety of these combinations in Chinese IBD patients.
methodsCombination therapy is defined as the simultaneous use of two biologics or one biologic combined with a small molecule drug. The demographic data, laboratory test results, disease characteristics, and adverse events were recorded. Treatment efficacy was evaluated based on clinical response and remission, and endoscopic response and remission, according to the Patient-Reported Outcome-2 system, Simplified Endoscopic Score-Crohn's Disease system, Mayo score, and Mayo Endoscopic Score. Safety was determined based on the occurrence of adverse events.
resultsTwenty-three Crohn's disease and five ulcerative colitis patients underwent combination therapy. The most common combination therapy was vedolizumab combined with ustekinumab (20/28, 71.40%). Based on the intention-to-treat analysis, the overall clinical response rate was 22/28 (78.60%), and 16/28 (57.10%) patients achieved clinical remission. Among the 14 patients who underwent endoscopic evaluation, nine (64.30%) patients achieved endoscopic response, including seven (77.78%) patients who further achieved endoscopic remission. After treatment, C-reactive protein significantly decreased (8.10 [3.50-14.00] to 3.30 [2.20-8.80], p < 0.05), and albumin significantly increased (35.40 [33.80-40.00] to 41.10 [38.30-44.50], p < 0.05). No severe adverse events were reported.
conclusionsCombination therapy with biologics or small molecules demonstrates favorable potential in managing refractory IBD, and offers a viable treatment option for Chinese patients. However, further research is needed for validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.